Understanding Immune Privilege in an Inducible Mouse Model of Primary Cicatricial Alopecia

    U. Yildiz Altay, K. Afshari, N. Haddadi, D. Kwong, Renee Joyce, C. Li, S. Shakiba, J. Richmond
    Image of study
    TLDR The study found that a key immune pathway protecting hair follicles is reduced in a mouse model of scarring hair loss.
    This study investigates the role of immune privilege in primary cicatricial alopecia (PCA) using an inducible mouse model. PCA is characterized by scarring and irreversible hair loss due to CD8+ T cells attacking epithelial hair follicle stem cells (eHFSCs). Researchers used adoptive transfers of OT1 T cells into autoimmune-prone mice expressing ovalbumin under a keratin 5 promoter to induce skin fibrosis. Analysis of skin biopsies revealed significantly reduced CD200R expression in affected mouse skin, a pathway known for its immunoregulatory role in protecting hair follicles. The gene expression in this mouse model showed similarities with human conditions like LPP, CCCA, and DLE. The study aims to further explore hair follicle immune privilege breakdown to identify new treatment targets for scarring alopecia.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 282 results
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 3 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community We need to keep these snake oil companies accountable.

      in Treatment  121 upvotes 5 months ago
      Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

    Related Research

    4 / 4 results